A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Guardant Health, Inc.
GH
$18.5B
Mkt Cap
$147.33
-1.91%
Guardant Health, Inc. (GH) has a 5-year average return on invested capital (ROIC) of -35.2%. This is below average and may indicate limited pricing power.
Guardant Health, Inc. (GH) has a market capitalization of $19.4B. It is classified as a large-cap stock.
Guardant Health, Inc. (GH) does not currently pay a regular dividend.
Guardant Health, Inc. (GH) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
Guardant Health, Inc. (GH) reported annual revenue of $982 million in its most recent fiscal year, based on SEC EDGAR filings.
Guardant Health, Inc. (GH) has a net profit margin of -42.4%. The company is currently unprofitable.
Guardant Health, Inc. (GH) generated $-233 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For patients with advanced-stage cancer, we offer the Guardant360 Liquid test, formerly known as the Guardant360 LDT test, and the Guardant360 CDx test, the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration, or the FDA, to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, or NSCLC, colorectal cancer and breast cancer.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.1B | 982M | 739M | 564M | 450M | 374M |
| Net Income | -433M | -416M | -436M | -479M | -655M | -406M |
| EPS | $-3.38 | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 |
| Free Cash Flow | -237M | -233M | -275M | -345M | -387M | -284M |
| ROIC | -18.5% | -34.6% | -37.9% | -38.4% | -44.0% | -20.9% |
| Gross Margin | - | 64.5% | 60.8% | 59.7% | 7.1% | 22.4% |
| Debt/Equity | 0.00 | -17.22 | -9.57 | 8.53 | 22.75 | 2.13 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -448M | -437M | -444M | -565M | -544M | -411M |
| Operating Margin | -41.4% | -44.5% | -60.0% | -100.1% | -121.1% | -110.0% |
| ROE | 0.0% | 348.4% | - | -438.1% | -185.7% | -41.7% |
| Shares Outstanding | 132M | 125M | 123M | 112M | 102M | 101M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 25M | 50M | 91M | 214M | 287M | 374M | 450M | 564M | 739M | 982M | 1.1B |
| Gross Margin | N/A | N/A | 2.6% | 36.3% | 37.8% | 22.4% | 7.1% | 59.7% | 60.8% | 64.5% | N/A |
| R&D | 11M | 26M | 51M | 86M | 150M | 263M | 374M | 367M | 348M | 364M | 367M |
| SG&A | 9.9M | 37M | 36M | 61M | 193M | 207M | 164M | 156M | 180M | 211M | 222M |
| EBIT | -44M | -77M | -93M | -82M | -255M | -411M | -544M | -565M | -444M | -437M | -448M |
| Op. Margin | -173.7% | -153.7% | -102.5% | -38.4% | -88.9% | -110.0% | -121.1% | -100.1% | -60.0% | -44.5% | -41.4% |
| Net Income | -46M | -89M | -85M | -76M | -254M | -406M | -655M | -479M | -436M | -416M | -433M |
| Net Margin | -182.7% | -178.6% | -93.8% | -35.3% | -88.5% | -108.6% | -145.6% | -85.0% | -59.0% | -42.4% | -40.1% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 5.3M | 29M | 0 | 0 | 0 |
| Returns on Capital | |||||||||||
| ROIC | -56.6% | -45.8% | -21.5% | -11.8% | -17.5% | -20.9% | -44.0% | -38.4% | -37.9% | -34.6% | -18.5% |
| ROE | -56.6% | -45.8% | -21.5% | -11.8% | -24.2% | -41.7% | -185.7% | -438.1% | N/A | 348.4% | 0.0% |
| ROA | N/A | -51.9% | -18.3% | -9.8% | -15.7% | -18.1% | -34.3% | -28.2% | -26.7% | -23.8% | -22.6% |
| Cash Flow | |||||||||||
| Op. Cash Flow | -37M | -72M | -72M | -47M | -104M | -209M | -309M | -325M | -240M | -185M | -188M |
| Free Cash Flow | -38M | -79M | -92M | -66M | -140M | -284M | -387M | -345M | -275M | -233M | -237M |
| Owner Earnings | -42M | -81M | -86M | -75M | -264M | -383M | -440M | -459M | -423M | -391M | -403M |
| CapEx | 1.8M | 6.7M | 20M | 19M | 36M | 75M | 77M | 20M | 35M | 48M | 49M |
| Maint. CapEx | 3.7M | 5.2M | 7.1M | 11M | 16M | 22M | 36M | 43M | 42M | 40M | 39M |
| Growth CapEx | 0 | 1.5M | 13M | 7.3M | 20M | 53M | 41M | 0 | 0 | 8.6M | 10M |
| D&A | 3.7M | 5.2M | 7.1M | 11M | 16M | 22M | 36M | 43M | 42M | 40M | 39M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 100K | 7.2M | 172K | 0 | 0 | 0 | 0 | 0 | 0 | 45M | 0 |
| Buyback Yield | 0.0% | N/A | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | 0.3% | 0.0% |
| Stock-Based Comp | 2.0M | 3.7M | 6.9M | 17M | 144M | 151M | 95M | 91M | 140M | 166M | 176M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 784K | 0 | 0 | 0 | 25M | 25M |
| Balance Sheet | |||||||||||
| Net Debt | N/A | N/A | N/A | -482M | -940M | 441M | 358M | 185M | -94M | 74M | -604M |
| Cash & Equiv. | 34M | 72M | 141M | 143M | 833M | 492M | 142M | 1.1B | 526M | 378M | 2.1B |
| Long-Term Debt | N/A | N/A | N/A | 0 | 806M | 1.1B | 1.1B | 1.1B | 1.1B | 1.5B | 1.5B |
| Debt/Equity | 0.01 | 0.11 | 0.13 | 0.05 | 0.66 | 2.13 | 22.75 | 8.53 | -9.57 | -17.22 | 0.00 |
| Interest Coverage | -14.5 | -28.4 | -74.3 | -69.7 | -53.5 | -159.5 | -211.2 | -219.1 | -171.9 | -112.2 | -112.2 |
| Equity | 80M | 309M | 483M | 798M | 1.3B | 645M | 60M | 159M | -140M | -99M | -181M |
| Total Assets | N/A | 343M | 587M | 963M | 2.3B | 2.2B | 1.6B | 1.8B | 1.5B | 2.0B | 1.9B |
| Total Liabilities | 508K | 34M | 62M | 115M | 916M | 1.6B | 1.5B | 1.6B | 1.6B | 2.1B | 2.1B |
| Intangibles | N/A | N/A | 0 | 8.5M | 16M | 14M | 12M | 9.0M | 6.8M | 26M | 26M |
| Retained Earnings | N/A | -196M | -281M | -353M | -607M | -1.0B | -1.7B | -2.1B | -2.6B | -3.0B | -3.1B |
| Working Capital | N/A | 223M | 422M | 525M | 1.8B | 919M | 998M | 1.1B | 830M | 1.2B | 1.1B |
| Current Assets | N/A | 243M | 469M | 597M | 1.9B | 1.1B | 1.2B | 1.3B | 1.1B | 1.5B | 1.4B |
| Current Liabilities | N/A | 20M | 47M | 73M | 67M | 195M | 193M | 206M | 226M | 303M | 292M |
| Per Share Data | |||||||||||
| EPS | -3.53 | -7.07 | -0.99 | -0.84 | -2.60 | -4.00 | -6.41 | -4.28 | -3.56 | -3.32 | -3.38 |
| Owner EPS | -3.24 | -6.44 | -1.00 | -0.84 | -2.71 | -3.77 | -4.31 | -4.09 | -3.45 | -3.12 | -3.06 |
| Book Value | 6.10 | 24.52 | 5.63 | 8.87 | 13.30 | 6.36 | 0.59 | 1.42 | -1.14 | -0.79 | -1.38 |
| Cash Flow/Share | -2.81 | -5.74 | -0.84 | -0.52 | -1.06 | -2.06 | -3.03 | -2.90 | -1.96 | -1.47 | -3.00 |
| Dividends/Share | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 13.1M | 12.6M | 85.8M | 90.1M | 97.6M | 101.4M | 102.1M | 112.0M | 122.6M | 125.4M | 131.5M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -43.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 7.4 | 8.9 | 9.5 | 15.1 | 43.2 | 19.7 | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | 38.3 | 30.6 | 30.8 | 34.5 | 12.4 | 5.9 | 4.2 | 7.3 | 17.9 |
| FCF Yield | N/A | N/A | -2.6% | -0.9% | -1.1% | -2.9% | -14.9% | -11.1% | -7.4% | -1.8% | -1.2% |
| Market Cap | 0 | N/A | 3.6B | 7.1B | 12.4B | 9.7B | 2.6B | 3.1B | 3.7B | 12.9B | 19.4B |
| Avg. Price | 0.00 | N/A | 36.83 | 72.87 | 90.60 | 126.97 | 54.63 | 29.65 | 25.31 | 57.52 | 147.33 |
| Year-End Price | 0.00 | N/A | 37.71 | 78.81 | 126.68 | 96.01 | 25.44 | 27.86 | 30.44 | 102.98 | 147.33 |
Guardant Health, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 42.9%.
Guardant Health, Inc. (GH) reported earnings per share (EPS) of $-3.32 in its most recent fiscal year.
Guardant Health, Inc. (GH) has a return on equity (ROE) of 348.4%. This indicates the company generates strong returns for shareholders.
Guardant Health, Inc. (GH) has a 5-year average gross margin of 42.9%. This indicates decent pricing power.
The Ledger Terminal provides 10 years of financial data for Guardant Health, Inc. (GH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Guardant Health, Inc. (GH) has a book value per share of $-0.79, based on its most recent annual SEC filing.